Tirzepatide vial

Tirzepatide Peptide – Premium Dual GIP/GLP-1 Receptor Agonist for Research

Introducing Tirzepatide Peptide, a cutting-edge synthetic polypeptide designed as a dual agonist for glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Known in scientific circles as the groundbreaking “twincretin,” this 39-amino-acid peptide (with a C20 fatty diacid side chain for extended half-life) represents one of the most potent incretin-based compounds available for advanced metabolic and endocrine research.

Originally developed as a long-acting analog, tirzepatide exhibits superior receptor activation compared to single incretin agonists, making it a cornerstone molecule in studies exploring glucose homeostasis, energy balance, appetite regulation, and body composition dynamics.

Key Research Applications & Observed Effects:

• Enhanced Glycemic Control — Stimulates glucose-dependent insulin secretion from pancreatic beta cells while suppressing glucagon release from alpha cells, supporting investigations into type 2 diabetes mechanisms and insulin sensitivity.
• Significant Appetite & Satiety Modulation — Activates central and peripheral pathways to reduce food intake, delay gastric emptying, and promote feelings of fullness—ideal for obesity, metabolic syndrome, and neuroendocrinology studies.
• Robust Weight & Fat Mass Reduction — Demonstrates substantial effects on body weight, fat mass loss (with preservation of lean mass in many models), and adipose tissue metabolism in preclinical and clinical research settings.
• Cardiometabolic Benefits — Supports exploration of lipid profile improvements, inflammation reduction, and potential cardiovascular protective effects linked to incretin signaling.
• Multi-Organ Metabolic Impact — Influences insulin sensitivity in liver, muscle, and adipose tissue; modulates energy expenditure and substrate utilization.

Product Highlights:

• High-purity, synthetic tirzepatide (≥98–99% purity via HPLC)
• Reduced, bioactive form with extended half-life (~5 days) for convenient once-weekly research protocols
• Lyophilized powder format for stability and reconstitution flexibility
• Commonly supplied in research vials (e.g., 5 mg, 10 mg, 20 mg+)